How Analysts Feel About Arqule Inc (NASDAQ:ARQL) After Decrease in Sellers?

September 16, 2018 - By Kyle Williams

ArQule, Inc. (NASDAQ:ARQL) Logo

The stock of Arqule Inc (NASDAQ:ARQL) registered a decrease of 7.62% in short interest. ARQL’s total short interest was 5.64M shares in September as published by FINRA. Its down 7.62% from 6.10 million shares, reported previously. With 1.17M shares average volume, it will take short sellers 5 days to cover their ARQL’s short positions.

The stock increased 1.48% or $0.08 during the last trading session, reaching $5.47. About 828,423 shares traded. ArQule, Inc. (NASDAQ:ARQL) has risen 397.32% since September 16, 2017 and is uptrending. It has outperformed by 381.70% the S&P500.

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company has market cap of $595.23 million. The Company’s lead product candidate is tivantinib , a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer. It currently has negative earnings. The companyÂ’s clinical-stage products include ARQ 087, a multi-kinase inhibitor of the fibroblast growth factor receptor family Phase II clinical trial for patients with intrahepatic cholangiocarcinoma and in Phase Ib for multiple oncology indications; ARQ 092, an inhibitor of the AKT serine/threonine kinase in Phase I clinical trials for multiple oncology indications; ARQ 751, a next-generation inhibitor of AKT in Phase I clinical trial for solid tumors; and ARQ 761, an intravenously administered analogue of Beta-lapachone, which is Phase 1b clinical trial used as a promoter of NQo1-mediated programmed cancer cell death.

ArQule, Inc. (NASDAQ:ARQL) Ratings Coverage

Among 3 analysts covering Arqule (NASDAQ:ARQL), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Arqule had 3 analyst reports since April 5, 2018 according to SRatingsIntel. The stock of ArQule, Inc. (NASDAQ:ARQL) has “Buy” rating given on Monday, June 11 by Oppenheimer. FBR Capital maintained the shares of ARQL in report on Friday, June 29 with “Buy” rating. The firm has “Buy” rating by Leerink Swann given on Thursday, April 5.

More recent ArQule, Inc. (NASDAQ:ARQL) news were published by: Nasdaq.com which released: “Analysis: Positioning to Benefit within PagSeguro Digital, ChannelAdvisor, Transocean, Arcos Dorados, Precision …” on August 21, 2018. Also Benzinga.com published the news titled: “30 Stocks Moving In Wednesday’s Pre-Market Session” on September 12, 2018. Seekingalpha.com‘s news article titled: “ArQule receives Fast Track Designation for Miransertib for the treatment of PROS” with publication date: September 13, 2018 was also an interesting one.

ArQule, Inc. (NASDAQ:ARQL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.